Table of Content


Chapter 1. Global Cancer Therapeutics and Biotherapeutics Market Executive Summary
1.1. Global Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
?1.3.1. By Product Type
?1.3.2. By Application
?1.3.3. By End-use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendations & Conclusion
Chapter 2. Global Cancer Therapeutics and Biotherapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
?2.3.1. Inclusion & Exclusion
?2.3.2. Limitations
?2.3.3. Supply-Side Analysis
??2.3.3.1. Infrastructure & Capacity
??2.3.3.2. Regulatory Environment
??2.3.3.3. Manufacturing Complexity
??2.3.3.4. Economic Viability (Provider’s Perspective)
?2.3.4. Demand-Side Analysis
??2.3.4.1. Oncology Treatment Adoption
??2.3.4.2. Payer & Reimbursement Trends
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Cancer Therapeutics and Biotherapeutics Market Dynamics
3.1. Market Drivers
?3.1.1. Rising Cancer Incidence and Early-Detection Programs
?3.1.2. Advances in Targeted and Immuno-Oncology Therapies
?3.1.3. Supportive Regulatory Frameworks for Biotherapeutics
3.2. Market Challenges
?3.2.1. High R&D and Manufacturing Costs
?3.2.2. Complex Clinical Trial Requirements
?3.2.3. Limited Access in Emerging Economies
3.3. Market Opportunities
?3.3.1. Growth of Biosimilars and Biobetters
?3.3.2. AI-Driven Drug Discovery and Personalized Medicine
?3.3.3. Expansion of Outpatient and Home-Based Oncology Care
Chapter 4. Global Cancer Therapeutics and Biotherapeutics Market Industry Analysis
4.1. Porter’s Five Forces
?4.1.1. Bargaining Power of Suppliers
?4.1.2. Bargaining Power of Buyers
?4.1.3. Threat of New Entrants
?4.1.4. Threat of Substitutes
?4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
?4.2.1. Political
?4.2.2. Economic
?4.2.3. Social
?4.2.4. Technological
?4.2.5. Environmental
?4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Winning Market Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendations & Conclusion
Chapter 5. Global Cancer Therapeutics and Biotherapeutics Market Size & Forecasts by Product Type (2022–2032)
5.1. Segment Dashboard
5.2. Chemotherapy: Revenue Trend Analysis, 2022 & 2032
5.3. Hormone Therapy: Revenue Trend Analysis, 2022 & 2032
5.4. Radiation Therapy: Revenue Trend Analysis, 2022 & 2032
5.5. Biotherapy: Revenue Trend Analysis, 2022 & 2032
5.6. Others: Revenue Trend Analysis, 2022 & 2032
Chapter 6. Global Cancer Therapeutics and Biotherapeutics Market Size & Forecasts by Application (2022–2032)
6.1. Segment Dashboard
6.2. Lung Cancer: 2022 & 2032
6.3. Blood Cancer: 2022 & 2032
6.4. Breast Cancer: 2022 & 2032
6.5. Prostate Cancer: 2022 & 2032
6.6. Others: 2022 & 2032
Chapter 7. Global Cancer Therapeutics and Biotherapeutics Market Size & Forecasts by End-use (2022–2032)
7.1. Segment Dashboard
7.2. Hospital: 2022 & 2032
7.3. Ambulatory Surgical Centers (ASC): 2022 & 2032
7.4. Others: 2022 & 2032
Chapter 8. Global Cancer Therapeutics and Biotherapeutics Market Size & Forecasts by Region (2022–2032)
8.1. North America
?8.1.1. U.S. Market
?8.1.2. Canada Market
8.2. Europe
?8.2.1. UK Market
?8.2.2. Germany Market
?8.2.3. France Market
?8.2.4. Spain Market
?8.2.5. Italy Market
?8.2.6. Rest of Europe Market
8.3. Asia Pacific
?8.3.1. China Market
?8.3.2. India Market
?8.3.3. Japan Market
?8.3.4. Australia Market
?8.3.5. South Korea Market
?8.3.6. Rest of Asia Pacific Market
8.4. Latin America
?8.4.1. Brazil Market
?8.4.2. Mexico Market
?8.4.3. Rest of Latin America Market
8.5. Middle East & Africa
?8.5.1. Saudi Arabia Market
?8.5.2. South Africa Market
?8.5.3. Rest of Middle East & Africa Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
?9.1.1. F. Hoffmann-La Roche Ltd.
?9.1.2. Bristol-Myers Squibb Company
?9.1.3. Pfizer Inc.
9.2. Top Market Strategies
9.3. Company Profiles
?9.3.1. F. Hoffmann-La Roche Ltd.
??9.3.1.1. Key Information
??9.3.1.2. Overview
??9.3.1.3. Financial (Subject to Data Availability)
??9.3.1.4. Product Summary
??9.3.1.5. Market Strategies
?9.3.2. Bristol-Myers Squibb Company
?9.3.3. Pfizer Inc.
?9.3.4. Amgen Inc.
?9.3.5. Merck & Co., Inc.
?9.3.6. Novartis AG
?9.3.7. AbbVie Inc.
?9.3.8. AstraZeneca plc
?9.3.9. Johnson & Johnson
?9.3.10. Bayer AG
?9.3.11. Eli Lilly and Company
?9.3.12. Gilead Sciences, Inc.
?9.3.13. Sanofi S.A.
?9.3.14. Takeda Pharmaceutical Company Limited
?9.3.15. Regeneron Pharmaceuticals, Inc.
Chapter 10. Research Process
10.1. Data Mining
10.2. Analysis
10.3. Market Estimation
10.4. Validation
10.5. Publishing
10.6. Research Attributes



List of Figures

List of Tables
TABLE 1. Global Cancer Therapeutics and Biotherapeutics Market, Report Scope
TABLE 2. Global Market Estimates & Forecasts by Region (2022–2032)
TABLE 3. Global Market Estimates & Forecasts by Product Type (2022–2032)
TABLE 4. Global Market Estimates & Forecasts by Application (2022–2032)
TABLE 5. Global Market Estimates & Forecasts by End-use (2022–2032)
TABLE 6. North America Market Estimates & Forecasts, 2022–2032
TABLE 7. U.S. Market Estimates & Forecasts by Segment, 2022–2032
TABLE 8. Canada Market Estimates & Forecasts by Segment, 2022–2032
TABLE 9. Europe Market Estimates & Forecasts, 2022–2032
TABLE 10. Asia Pacific Market Estimates & Forecasts, 2022–2032
TABLE 11. Latin America Market Estimates & Forecasts, 2022–2032
TABLE 12. Middle East & Africa Market Estimates & Forecasts, 2022–2032
TABLE 13. Competitive Landscape: Market Shares of Top 10 Companies (2023)
TABLE 14. R&D Expenditure of Leading Players (2022)
TABLE 15. Sales Breakdown by Therapy Class (2023)
TABLE 16. Application-Wise Incidence vs. Market Size Correlation (2022)
TABLE 17. Hospital vs. ASC Utilization Rates (2023)
TABLE 18. Regional Pricing and Reimbursement Comparison (2023)
TABLE 19. Clinical Trial Pipelines by Product Type (2023)
TABLE 20. Forecasted Impact of Biosimilars on Market Growth

List of Tables

List of Tables
TABLE 1. Global Cancer Therapeutics and Biotherapeutics Market, Report Scope
TABLE 2. Global Market Estimates & Forecasts by Region (2022–2032)
TABLE 3. Global Market Estimates & Forecasts by Product Type (2022–2032)
TABLE 4. Global Market Estimates & Forecasts by Application (2022–2032)
TABLE 5. Global Market Estimates & Forecasts by End-use (2022–2032)
TABLE 6. North America Market Estimates & Forecasts, 2022–2032
TABLE 7. U.S. Market Estimates & Forecasts by Segment, 2022–2032
TABLE 8. Canada Market Estimates & Forecasts by Segment, 2022–2032
TABLE 9. Europe Market Estimates & Forecasts, 2022–2032
TABLE 10. Asia Pacific Market Estimates & Forecasts, 2022–2032
TABLE 11. Latin America Market Estimates & Forecasts, 2022–2032
TABLE 12. Middle East & Africa Market Estimates & Forecasts, 2022–2032
TABLE 13. Competitive Landscape: Market Shares of Top 10 Companies (2023)
TABLE 14. R&D Expenditure of Leading Players (2022)
TABLE 15. Sales Breakdown by Therapy Class (2023)
TABLE 16. Application-Wise Incidence vs. Market Size Correlation (2022)
TABLE 17. Hospital vs. ASC Utilization Rates (2023)
TABLE 18. Regional Pricing and Reimbursement Comparison (2023)
TABLE 19. Clinical Trial Pipelines by Product Type (2023)
TABLE 20. Forecasted Impact of Biosimilars on Market Growth